Sep 19, 2023 4:01 pm EDT Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
Sep 01, 2023 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 31, 2023 4:01 pm EDT Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
Aug 08, 2023 4:01 pm EDT Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
Aug 04, 2023 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 01, 2023 4:01 pm EDT Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Jul 31, 2023 4:01 pm EDT Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Jul 07, 2023 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 07, 2023 4:01 pm EDT Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
Jun 05, 2023 9:00 am EDT Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023